Table 1.
Formulation of docetaxel solid lipid nanoparticles.
| Ingredient | BSLN | DSLN1 | DSLN2 | DSLN3 | DSLN4 |
|---|---|---|---|---|---|
| Docetaxel | --- | 5 mg | 5 mg | 5 mg | 5 mg |
| Rubone | --- | --- | 15 μg | 20 μg | 20 μg |
| Cetyl palmitate | 20 mg | 20 mg | 20 mg | 20 mg | 20 mg |
| PC | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg |
| Brij O10 | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg |
| Soluplus | 20 mg | 20 mg | 20 mg | 20 mg | 20 mg |
| LHRH | --- | --- | --- | --- | 20 μg |
| Water qs | 2 mL | 2 mL | 2 mL | 2 mL | 2 mL |
Figure 1.
Binding pockets detected in the crystallographic structure of LRP6 protein, which are located between two main b-propeller domains with docked cetyl palmitate.
Table 2.
Particle size, polydispersity index, zeta potential, and conductivity.
| Formulation | Particle size (nm) | Polydispersity index | Zeta potential (mV) | Conductivity (mS/cm) |
|---|---|---|---|---|
| BSLN | 63.26±3.0 | 0.087±0.01 | −14.53±2.0 | 0.087 ± 0.002 |
| DSLN1 | 174.93±3.0 | 0.344±0.06 | −14.33±0.5 | 0.091±0.001 |
| DSLN2 | 148.03±4.0 | 0.201±0.01 | −8.2±0.3 | 0.161±0.002 |
| DSLN3 | 125.77±3.0 | 0.237±0.01 | −9.27±0.2 | 0.113±0.001 |
| DSLN4 | 174.87±5.0 | 0.393±0.02 | −7.35±2.2 | 0.115±0.002 |
Figure 2.
Time-dependent particle size of docetaxel nanoformulations at 25 °C
Table 3.
Effect of 2 months storage at 4 °C on particle size and polydispersity index.
| BSLN | DSLN1 | DSLN2 | DSLN3 | DSLN4 | |
|---|---|---|---|---|---|
| Particle size (nm) | 61.8±0.2 | 406.5 ±8.8 | 159.7 ±2.5 | 139.6 ±0.9 | 123.7 ±2.6 |
| Polydispersity index | 0.079 ±0.003 | 0.472 ±0.020 | 0.189 ±0.007 | 0.208 ±0.008 | 0.205 ±0.003 |
Figure 3.
Images showing shapes of DSLN1 (a), DSLN2 (b), DSLN3 (c), DSLN4 (d) and BSLN (e) nanoparticles.
Figure 4.
FTIR spectra of docetaxel nanoparticle components.
Table 4.
Drug loading and entrapment for docetaxel-based nanoparticles.
| Formulation | Entrapment efficiency (%) | Drug loading capacity (%) |
|---|---|---|
| DSLN1 | 73.00 ± 3.0 | 9.30 ± 0.35 |
| DSLN2 | 80.00 ± 2.0 | 10.20 ± 0.13 |
| DSLN3 | 84.00 ± 3.0 | 10.80 ± 0.09 |
| DSLN4 | 81.20 ± 2.0 | 10.40 ± 0.06 |
Figure 5.
Docetaxel solid lipid nanoparticles' release profile.
Table 5.
Flux and permeability coefficient of DTX entrapped in lipid nanoparticles across dialysis membrane.
| Batch | Flux, J (μg/cm2 h) | Permeability coefficient (cm h−1) |
|---|---|---|
| DTX | 0.8482±0.0154 | 0.00033928±0 |
| DSLN1 | 0.748±0.0181 | 0.0002992±0 |
| DSLN3 | 0.8276±0.0227 | 0.00033104±0 |
| DSLN4 | 0.7032± 0.0236 | 0.00028128±0 |
Figure 6.
Percent viability of prostate cancer cell line DU145 after treatment with test nanoparticles.